fluphenazine has been researched along with Parkinson Disease in 18 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia." | 5.04 | A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. ( Bradley, R; Lamb, P; Mindham, RH, 1977) |
| "Relapse was accompanied by a resurgence of specifically schizophrenic symptoms and by an increase in abnormalities described by the relatives." | 2.64 | Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. ( Gaind, R; Hirsch, SR; Rohde, PD; Stevens, BC; Wing, JK, 1973) |
| "The comorbidity of schizophrenia and idiopathic Parkinson's disease (IPD) is illustrated by a case description of a schizophrenic patient who develops motor symptoms finally diagnosed and treated as comorbid IPD." | 1.40 | Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease. ( de Jong, MH; Van Gool, AR; Zemel, D, 2014) |
| "The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole." | 1.28 | Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. ( Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (83.33) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Jong, MH | 1 |
| Zemel, D | 1 |
| Van Gool, AR | 1 |
| KRUSE, W | 1 |
| Sheppard, C | 1 |
| Merlis, S | 1 |
| Mukherjee, S | 1 |
| Rosen, AM | 1 |
| Cardenas, C | 1 |
| Varia, V | 1 |
| Olarte, S | 1 |
| Weiner, WJ | 1 |
| Luby, ED | 1 |
| Martin, IC | 1 |
| Mindham, RH | 2 |
| Lamb, P | 1 |
| Bradley, R | 1 |
| Stimmel, GL | 1 |
| Elliott, PJ | 2 |
| Close, SP | 2 |
| Walsh, DM | 2 |
| Hayes, AG | 2 |
| Marriott, AS | 2 |
| Boelkins, RC | 1 |
| Gaind, R | 2 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Hirsch, SR | 1 |
| Rohde, PD | 1 |
| Stevens, BC | 1 |
| Wing, JK | 1 |
| Itil, TM | 1 |
| Patterson, CD | 1 |
| Keskiner, A | 1 |
| Holden, JM | 1 |
| Dreyfuss, J | 1 |
| Beer, B | 1 |
| Devine, DD | 1 |
| Roberts, BF | 1 |
| Schreiber, EC | 1 |
| Diemath, HE | 1 |
| Enge, S | 1 |
| Lechner, H | 1 |
| Strang, RR | 1 |
| Kurland, AA | 1 |
| Dim, BH | 1 |
| Olsson, JE | 1 |
5 trials available for fluphenazine and Parkinson Disease
| Article | Year |
|---|---|
Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
Topics: Adult; Aged; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic; Delayed-Action Preparat | 1975 |
A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
Topics: Chronic Disease; Clinical Trials as Topic; Fluphenazine; Humans; Parkinson Disease; Parkinson Diseas | 1977 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Clinical Trials as Topic; Delayed-Action | 1973 |
Comparison of phenothiazine and nonphenothiazine neuroleptics according to psychopathology, side effects and computerized EEG.
Topics: Alpha Rhythm; Chronic Disease; Clinical Trials as Topic; Computers; Electroencephalography; Female; | 1974 |
13 other studies available for fluphenazine and Parkinson Disease
| Article | Year |
|---|---|
Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease.
Topics: Antiparkinson Agents; Antipsychotic Agents; Brain; Carbidopa; Catechols; Clozapine; Diagnosis, Diffe | 2014 |
Development of parkinsonism after gradual reduction of fluphenazine dosage.
Topics: Fluphenazine; Humans; Parkinson Disease; Parkinsonian Disorders | 1963 |
Drug-induced extrapyramidal symptoms: their incidence and treatment.
Topics: Chlorpromazine; Chlorprothixene; Extrapyramidal Tracts; Female; Fluphenazine; Humans; Male; Parasymp | 1967 |
Tardive dyskinesia in psychiatric outpatients: a study of prevalence and association with demographic, clinical, and drug history variables.
Topics: Age Factors; Ambulatory Care; Antipsychotic Agents; Delayed-Action Preparations; Delusions; Dentures | 1982 |
Persistent akathisia following neuroleptic withdrawal.
Topics: Akathisia, Drug-Induced; Female; Fluphenazine; Humans; Middle Aged; Parkinson Disease | 1983 |
Neuroleptics and the corpus striatum: clinical implications.
Topics: Acetylcholine; Basal Ganglia Diseases; Benztropine; Corpus Striatum; Dopamine; Fluphenazine; Haloper | 1976 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationsh | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Fluphenazine; | 1990 |
Reactions to fluphenazine hydrochloride by two adult male macaques.
Topics: Aggression; Animals; Behavior, Animal; Drinking Behavior; Drug Tolerance; Feeding Behavior; Fluphena | 1971 |
Fluphenazine-induced parkinsonism in the baboon: pharmacological and metabolic studies.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Carbon Isotopes; Chromatography, Thin Layer; Feces; Fe | 1972 |
EEG depth leads during stereotaxic brain surgery. A report on 117 cases (5 target points, effects of 13 different drugs).
Topics: Amides; Amygdala; Antimetabolites; Asparagine; Benzoates; Brain; Brain Diseases; Cerebrovascular Cir | 1970 |
The treatment of the "anxiety-tension syndrome", in Parkinson's disease with fluphenazine (Pacinol).
Topics: Adult; Aged; Anxiety; Delayed-Action Preparations; Female; Fluphenazine; Humans; Male; Middle Aged; | 1966 |
The effectiveness of parenteral administration of fluphenazine decanoate in the treatment of chronic schizophrenics.
Topics: Administration, Oral; Adult; Biperiden; Chronic Disease; Female; Fluphenazine; Humans; Infusions, Pa | 1970 |